Palvella Therapeutics
PVLA
197 hedge funds and large institutions have $2.15B invested in Palvella Therapeutics in 2026 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 88 increasing their positions, 42 reducing their positions, and 19 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 42
100% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 19
31% more capital invested
Capital invested by funds: $1.64B → $2.15B (+$508M)
9% more funds holding
Funds holding: 180 → 197 (+17)
2% more call options, than puts
Call options by funds: $37.9M | Put options by funds: $37M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
13.19% less ownership
Funds ownership: 111.44% → 98.25% (-13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$38.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28.7M |
| 3 |
BlackRock
New York
|
+$28.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$23.6M |
| 5 |
O
OrbiMed
New York
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$35M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$25.4M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$24.2M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$21.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11M |
PVLA Hedge Fund Activity: Q2 2026 in Review
197 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2026, worth a combined $2.15B — up 31% from $1.64B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PVLA positions and 19 closed out — a net gain of 19 holders — while 88 added to existing stakes and 42 trimmed.
The largest buyer was Jennison Associates, adding an estimated $38.8M. The largest seller was BVF Inc, cutting an estimated $35M.
- 197 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2026, up from 180 in Q1 2026.
- Funds reported $2.15B of Palvella Therapeutics stock for Q2 2026, up 31% quarter-over-quarter.
- 38 funds opened new Palvella Therapeutics positions in Q2 2026 and 19 closed out, a net change of +19 holders.
- The largest Palvella Therapeutics buyer in Q2 2026 was Jennison Associates, an estimated $38.8M added.
- The largest Palvella Therapeutics seller in Q2 2026 was BVF Inc, an estimated $35M sold.
Based on aggregated 13F filings for Q2 2026.